Raymond James Financial
HRMY icon

Raymond James Financial’s Harmony Biosciences HRMY Stock Holding History

Raymond James Financial’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,816
Closed -$1.17M – 5479
2026
Q1 		$1.17M Buy
41,816
+35,514
+564% +$1.16M ﹤0.01% 3748
2025
Q4 		$236K Sell
6,302
-76,238
-92% -$2.51M ﹤0.01% 4708
2025
Q3 		$2.27M Buy
82,540
+8,421
+11% +$290K ﹤0.01% 3078
2025
Q2 		$2.34M Sell
74,119
-73,045
-50% -$2.35M ﹤0.01% 2952
2025
Q1 		$4.88M Buy
147,164
+109,257
+288% +$3.92M ﹤0.01% 2344
2024
Q4 		$1.3M Buy
+37,907
New +$1.3M ﹤0.01% 3267

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's HRMY Position: Q2 2026 in Review

Raymond James Financial sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 41,816 shares — an estimated $1.17M sold.

Raymond James Financial first reported a position in HRMY in Q4 2024 and held it in 6 quarters. The position peaked at $4.88M in Q1 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Raymond James Financial reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 41,816 Harmony Biosciences shares in Q2 2026, an estimated $1.17M.
  • Raymond James Financial first reported a position in Harmony Biosciences in Q4 2024 and held it in 6 quarters.
  • Raymond James Financial's Harmony Biosciences position peaked at $4.88M in Q1 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.